Volume Spike Investor

Cell Therapeutics Inc. (NASDAQ: CTIC) is trading higher this morning after its special meeting Friday ad after a corporate update.  Weekend chat rooms and online posts were of course still very mixed on this one with the bulls touting a definite approval down the road and the bears touting that it has little to nothing [...]

Cell Therapeutics, Inc. (NASDAQ: CTIC) is up ahead of its special shareholder meeting; and after it announced that the company has received a FDA complete response letter over its new drug application for pixantrone for relapsed or refractory aggressive non-Hodgkin’s lymphoma.  It is going to keep marching forward with current and new indications.  Shares are [...]

We have many stocks on the move this morning.  Some are secondary offerings and many are on news and analyst calls.  Below is a snapshot on each with the news, the move, relative price and average daily volume and other pertinent color where applicable. American Superconductor Corporation (NASDAQ: AMSC) is launching after the company was [...]

The bull market is officially one-year old now.  March 9, 2009 was the absolute low for the index levels.  VSInvestor.com has pulled many of biggest stock movers from the Russell 2000 Index.  Amazingly, we had to include stocks which up a whopping 800% just to get the list down to close to 40 stocks.  This [...]

These are this Monday’s top day trader and active trader alerts seen in pre-market trading.  We have included the news and some brief color where applicable on each.  We have also given updates as of 9:15 to 9:18 AM EST: American International Group, Inc. (NYSE: AIG) is trading up 2% after its $15.5 billion Alico [...]

These are some of the top trading stocks seen on price and volume moves for day traders and active traders: Amgen Inc. (NASDAQ: AMGN) is trading up this morning by 2.25% at $58.75 on almost 200,000 shares on its report that its Phase III head-to-head trial evaluating Denosumab met its primary and secondary endpoints versus [...]

Cell Therapeutics, Inc. (NASDAQ: CTIC) is trading up after it disclosed data from the pivotal phase III EXTEND clinical trial of pixantrone in relapsed or refractory, aggressive non-Hodgkin’s lymphoma patients who have failed 2 or more prior therapies. The company noted that updated analysis with additional follow-up data  were conducted and support the initial clinical [...]

Cell Therapeutics, Inc. (NASDAQ: CTIC) is trading up again, this morning on news that it released updated 18-month follow-up clinical data for its phase III EXTEND trial of pixantrone pixantrone (BBR2778) for patients with advanced, relapsed or refractory, aggressive non-Hodgkin’s lymphoma (NHL).  This is different than its news from the E.U. filing yesterday.  CTIC said [...]

Cell Therapeutics Inc. (Nasdaq: CTIC) shares are up more than 8% on higher-than usual early volume after the company submitted a new drug application to the FDA for pixantrone to treat relapsed or refractory, aggressive non-Hodgkin’s lymphoma. The company has requested a priority review. If it’s granted it could lead to an FDA approval decision [...]

Cell Therapeutics, Inc. (NASDAQ: CTIC) is trading up big this morning and we have now crossed the 150% threshold of daily average trading volume.  Over the weekend, there was a report from BiomedReports calling the company’s turnaround plan as being on track.  This is after much narrower losses last week.  Shares are up 20% at [...]